Drugs / Rilematovir
Rilematovir
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT05155007 | Dec 2021 → Feb 2022 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04332523 | Aug 2020 → Mar 2022 | — | Janssen Research & Development, LLC | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04090086 | Sep → Dec 2019 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03696459 | Oct 2018 → Dec 2019 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03002779 | Jan → Mar 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02945007 | Nov 2016 → Jan 2020 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02729467 | Mar → Jun 2016 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02593851 | Dec 2015 → Mar 2017 | respiratory syncytial virus infectious disease | Janssen Sciences Ireland UC | Terminated | No outcome recorded |
| Phase 1 | NCT02398591 | Apr → Jul 2015 | — | Janssen Sciences Ireland UC | Completed | No outcome recorded |
| Phase 1 | NCT02426632 | Mar → Apr 2015 | — | Janssen Sciences Ireland UC | Completed | No outcome recorded |
| Phase 25 trials · 2 missed | ||||||
| Phase 2 | NCT04978337 | Nov 2021 → Mar 2022 | respiratory syncytial virus infectious disease | Janssen Research & Development, LLC | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04056611 | Dec 2019 → Feb 2022 | respiratory syncytial virus infectious disease | Janssen Sciences Ireland UC | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04068792 | Oct 2019 → May 2021 | respiratory syncytial virus infectious disease | Janssen Research & Development, LLC | Completed | Missed primary |
| Phase 2 | NCT03656510 | Nov 2018 → Apr 2022 | respiratory syncytial virus infectious disease | Janssen Research & Development, LLC | Terminated | Missed primary Stop: Business |
| Phase 2 | NCT02387606 | May → Sep 2015 | respiratory syncytial virus infectious disease | Janssen Sciences Ireland UC | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04583280 | Sep 2021 → Mar 2022 | respiratory tract infectious disorder | Janssen Research & Development, LLC | Terminated | No outcome recorded Stop: Business |
| Phase not stated1 trial | ||||||
| — | NCT04221412 | — | respiratory syncytial virus infectious disease | Janssen Sciences Ireland UC | No longer available | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rilematovir | “Rilematovir is an investigational, orally administered inhibitor of RSV fusion protein-mediated viral entry.” PMID 38649595 ↗ Apr 2024 |
| Known as | JNJ-53718678 | “A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection” NCT04978337 ↗14“taste of different JNJ-53718678 oral liquid formulations” NCT02426632 ↗ |
| Known as | JNJ-8678 | “the respiratory syncytial virus (RSV)-specific fusion inhibitor JNJ-53718678 (JNJ-8678) in hospitalized RSV-infected patients aged > 1 to ≤24 months.” PMID 32201897 ↗ Dec 2020 |
| Action | Inhibit | “JNJ-53718678 is a fusion inhibitor with selective activity against RSV.” PMID 29684148 ↗ Jul 2018 |
| Modality | Other / unclassified | “respiratory syncytial virus (RSV)-specific fusion inhibitor JNJ-53718678” PMID 32201897 ↗ Dec 2020 |
| Route | Oral | “JNJ-53718678 as 20 milliliter (mL) (200 mg) or 50 mL (500 mg) oral solution” NCT02387606 ↗ |